OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders to convert $55.42 million of its 4.50% Convertible Senior Notes due 2025 into shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders to convert $55.42 million of its 4.50% Convertible Senior Notes due 2025 into shares of common stock. The exchange will be based on a volume-weighted average price with a floor price of $3.50 per share, starting today. Additionally, OPKO will pay accrued interest to the noteholders in cash. This move is expected to reduce the outstanding borrowed shares related to a previous share lending agreement with Jefferies Capital Services.
Positive
- Conversion of $55.42 million of notes to common stock, potentially improving balance sheet.
Negative
- None.
Details
News Market Reaction – OPK
The recorded move for OPK in the trading session of this news was -5.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 07, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders of the Company’s
The number of shares of common stock to be issued by the Company to the Noteholders will be determined based upon a volume-weighted-average-price per share of common stock, subject to a floor price of
As announced in February 2019, in connection with the Company’s original issuance of its
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the expected reduction in the outstanding borrowed shares of common stock. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.